BioCrossroads announces leadership transitions—David L. Johnson to join CICP as full-time President and CEO; Nora Doherty to serve as BioCrossroads’ interim leader

12/12/2018

After 14 years as president and CEO, David L. Johnson will leave the organization, effective December 31, 2018, to assume his responsibilities as president and CEO of the Central Indiana Corporate Par

BioCrossroads announced today that after 14 years as president and CEO, David L. Johnson will leave the organization, effective December 31, 2018, to assume his responsibilities as president and CEO of the Central Indiana Corporate Partnership (CICP) on a full-time basis. In December 2012, Johnson was elected president and CEO of CICP and has led both organizations in shared capacities since that time.  Nora Doherty, currently senior vice president of BioCrossroads and managing director of the Indiana Seed Funds, has been named by the BioCrossroads Board of Directors to serve as interim president and CEO until a permanent president and CEO is selected through a national search process.

For more information, visit https://www.cicpindiana.com/davidjohnsoncicp/

2018 Annual Report cover

The IBRI 2018 Annual Report is now available. The report theme is “Discovery With Purpose,” which is also the IBRI’s motto as it reflects the Institute’s commitment to translating scientific discovery into improved outcomes for patients.